Test Report Status Final



Biological Reference Interval Units

PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : DR. BOB		
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061XC002081	AGE/SEX :48 Years Female	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KAVIF23037661	DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 24/03/2024 11:19:09	
NEW DELHI 110030	ABHA NO :	REPORTED :28/03/2024 15:15:16	
8800465156			
		<u> </u>	

Results

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		,	
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	11.9 Low	12.0 - 15.0	g/dL	
RED BLOOD CELL (RBC) COUNT	4.50	3.8 - 4.8	mil/µL	
WHITE BLOOD CELL (WBC) COUNT	7.04	4.0 - 10.0	thou/µL	
PLATELET COUNT	229	150 - 410	thou/µL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	39.5	36 - 46	%	
MEAN CORPUSCULAR VOLUME (MCV)	87.8	83 - 101	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.4 Low	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	30.1 Low	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW)	14.2 High	11.6 - 14.0	%	
MENTZER INDEX	19.5			
MEAN PLATELET VOLUME (MPV)	10.9	6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	69	40 - 80	%	
LYMPHOCYTES	23	20 - 40	%	
MONOCYTES	03	2 - 10	%	
EOSINOPHILS	05	1 - 6	%	
BASOPHILS	00	< 1 - 2	%	

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.



Dr. Tarun Sharma **Consultant Pathologist**



Dr. Itisha Dhiman Pathologist





View Report

Page 1 Of 17

View





PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : DR. BOB		
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID:	AGE/SEX :48 Years Female DRAWN : RECEIVED :24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16	
Test Report Status Final	Results Biological	Reference Interval Units	

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR <

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Tarun Sharma **Consultant Pathologist**



Dr. Itisha Dhiman Pathologist



View Details



Page 2 Of 17





PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : D	R. BOB
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0061XC002081 PATIENT ID : KAVIF23037661 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :48 Years Female DRAWN : RECEIVED :24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

HAEMATOLOGY				
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE			
ERYTHROCYTE SEDIMENTATION RATE (ESR BLOOD	R),EDTA			
E.S.R METHOD : WESTERGREN METHOD	10	0 - 20	mm at 1 hr	
GLYCOSYLATED HEMOGLOBIN(HBA1C), ED BLOOD	TA WHOLE			
HBA1C	5.7	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%	
ESTIMATED AVERAGE GLUCOSE(EAG)	116.9 High	< 116.0	mg/dL	

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays' fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

gtisha.

Dr. Tarun Sharma

Consultant Pathologist

Dr. Itisha Dhiman Pathologist





Page 3 Of 17





PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : DR. BOB		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0061XC002081 PATIENT ID : KAVIF23037661 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :48 Years Female DRAWN : RECEIVED :24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16	
Test Report Status Final	Results Biological	Reference Interval Units	

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

Identifying patients at increased risk for diabetes (prediabetes).
 The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
 AGA (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to : 1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin. 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, failed increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist**





Page 4 Of 17

View Details





PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : DR. BOB		
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0061XC002081 PATIENT ID : KAVIF23037661	AGE/SEX : 48 Years Female DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030		RECEIVED : 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16	
8800465156			

Test Report Status Final

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE B METHOD : FORWARD/REVERSE POSITIVE METHOD : FORWARD/REVERSE VITIVE

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Tarun Sharma Consultant Pathologist



Dr. Itisha Dhiman Pathologist



Page 5 Of 17

View Report

View Details





PATIENT NAME : KAVIA SANTOSH		REF. DOCTOR : DR. BOB	
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 006	1XC002081 AGE/SEX	:48 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KAV	IF23037661 DRAWN	:
-703, LADO SARAI, MEHRAULISOUTH WES	CLIENT PATIENT ID:		: 24/03/2024 11:19:09
	ABHA NO :		:28/03/2024 15:15:16
NEW DELHI 110030			20/03/2021 13:13:10
3800465156			
Test Report Status <u>Final</u>	Results	Biological Referenc	e Interval Units
	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECK	UP BELOW 40FEMALE		
GLUCOSE FASTING,FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR)	88	Normal : < 100 Pre-diabetes: 100- Diabetes: >/=126	mg/dL 125
METHOD : SPECTROPHOTOMETRY			
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : SPECTROPHOTOMETRY	106	70 - 140	mg/dL
LIPID PROFILE WITH CALCULATED LDL,	SERUM		
CHOLESTEROL, TOTAL	130	< 200 Desirable 200 - 239 Borderlir >/= 240 High	mg/dL ne High
METHOD : SPECTROPHOTOMETRY		,	
TRIGLYCERIDES	71	< 150 Normal 150 - 199 Borderlir 200 - 499 High >/=500 Very High	mg/dL ne High
METHOD : SPECTROPHOTOMETRY HDL CHOLESTEROL	51	< 40 Low	mg/dL
	JI	< 40 Low >/=60 High	nig/uL
METHOD : SPECTROPHOTOMETRY		- -	
CHOLESTEROL LDL	65	< 100 Optimal 100 - 129 Near optimal/ abov 130 - 159 Borderline High 160 - 189 High	mg/dL re optimal

L

Dr. Tarun Sharma Consultant Pathologist

gtisha

Dr. Itisha Dhiman Pathologist



View Details

>/= 190 Very High



Page 6 Of 17

Patient Ref. No. 775000006938956



PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : DR. BOB			
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0061 PATIENT ID : KAVII CLIENT PATIENT ID: ABHA NO :	XC002081 F23037661	AGE/SEX :48 Years Female DRAWN : RECEIVED :24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16	
Test Report Status <u>Final</u>	Results	Biological	Reference Interval Units	
NON HDL CHOLESTEROL	79	Above De Borderline High: 190	: Less than 130 mg/dL sirable: 130 - 159 e High: 160 - 189) - 219 : > or = 220	
VERY LOW DENSITY LIPOPROTEIN	14.2	= 30.0</td <td>mg/dL</td>	mg/dL	
CHOL/HDL RATIO	2.5 Low	3.3 - 4.4 Low Risk 4.5 - 7.0 Average F 7.1 - 11.0 Moderate > 11.0 High Risk) Risk	
LDL/HDL RATIO	1.3	0.5 - 3.0	Desirable/Low Risk Borderline/Moderate	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India			
Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemia	a	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ		
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age $>$ or $=$ 45 year	1. Age $>$ or = 45 years in males and $>$ or = 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Dr. Tarun Sharma Consultant Pathologist

gtisha

Dr. Itisha Dhiman Pathologist





Page 7 Of 17

View Details





PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : DR. BOB		
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0061XC002081 PATIENT ID : KAVIF23037661 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :48 Years Female DRAWN : RECEIVED :24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16	
Test Report Status <u>Final</u>	Results Biologica	al Reference Interval Units	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD : SPECTROPHOTOMETRY	0.30	0.2 - 1.0	mg/dL
BILIRUBIN, DIRECT	0.10	0.0 - 0.2	mg/dL
METHOD : SPECTROPHOTOMETRY BILIRUBIN, INDIRECT	0.20	0.1 - 1.0	mg/dL
METHOD : SPECTROPHOTOMETRY TOTAL PROTEIN	6.9	6.4 - 8.2	g/dL
METHOD : SPECTROPHOTOMETRY ALBUMIN	3.5	3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO	1.0	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER ASPARTATE AMINOTRANSFERASE(AST/SGOT)	18	15 - 37	U/L
METHOD : SPECTROPHOTOMETRY	40 High		U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : SPECTROPHOTOMETRY	40 mgn	< 34.0	·
ALKALINE PHOSPHATASE METHOD : SPECTROPHOTOMETRY	115	30 - 120	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : SPECTROPHOTOMETRY	36	5 - 55	U/L
	180	81 - 234	U/L

Dr. Tarun Sharma Consultant Pathologist

Dr. Itisha Dhiman Pathologist



Page 8 Of 17

View Report

View Details





Patient Ref. No. 775000006938956

PATIENT NAME : KAVIA SANTOSH		REF. DOCTOR : DR. BO	DB
CODE/NAME & ADDRESS : C000138375		51XC002081 AGE/	/SEX :48 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWH		/IF23037661 DRAV	WN :
F-703, LADO SARAI, MEHRAULISOUTH DELHI	CLIENT PATIENT ID:		EIVED : 24/03/2024 11:19:09
NEW DELHI 110030	ABHA NO :	REPC	DRTED :28/03/2024 15:15:16
8800465156			
Test Report Status <u>Final</u>	Results	Biological Refe	erence Interval Units
BLOOD UREA NITROGEN (BUN), SE	RUM		
BLOOD UREA NITROGEN	14	6 - 20	mg/dL
METHOD : SPECTROPHOTOMETRY			
CREATININE, SERUM			
CREATININE	0.71	0.60 - 1.10	mg/dL
METHOD : SPECTROPHOTOMETRY			
BUN/CREAT RATIO			
BUN/CREAT RATIO	19.72 High	5.00 - 15.00	
METHOD : SPECTROPHOTOMETRY			
URIC ACID, SERUM			
URIC ACID	4.2	2.6 - 6.0	mg/dL
METHOD : SPECTROPHOTOMETRY			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	6.9	6.4 - 8.2	g/dL
METHOD : SPECTROPHOTOMETRY			
ALBUMIN, SERUM			
ALBUMIN	3.5	3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY			
GLOBULIN			
GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
Te	stisha.		Page 9 Of 17
	Dr. /		
	. Itisha Dhiman		国际特殊国际国际等级委员 教教会成绩了,教教委委委员
Consultant Pathologist Pa	thologist		
PERFORMED AT :			View Details View Report



PATIENT NAME : KAVIA SANTOSH	REF. DOCTO	DR : DR. BOB
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061XC002081	AGE/SEX : 48 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KAVIF23037661	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 24/03/2024 11:19:09
NEW DELHI 110030	ABHA NO :	REPORTED :28/03/2024 15:15:16
8800465156		
Test Report Status <u>Final</u>	Results Biolog	gical Reference Interval Units

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM	140	136 - 145	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			
POTASSIUM, SERUM	4.2	3.50 - 5.10	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			
CHLORIDE, SERUM	111	98 - 107	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s) GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

1

Dr. Tarun Sharma **Consultant Pathologist**



Dr. Itisha Dhiman Pathologist





View Report

Page 10 Of 17

View Details





PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR :	DR. BOB
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0061XC002081 PATIENT ID : KAVIF23037661 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :48 Years Female DRAWN : RECEIVED :24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

urine

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides. Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents. NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

Real rational glucose level in comparison to post prantial glucose level may be seen due to effect of Oral Hypoglycaenics & Insulin treatment, kenal Glyosuria, Glycaenic below in comparison to post prantial glucose level may be seen due to effect of Oral Hypoglycaenics & Insulin treatment, Renal Glyosuria, Glycaenic index & response to food consumed, Alimentary Hypoglycaenia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM- **Bilirubin** is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

velow is coloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis.obstruction of bile ducts.cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels-Detary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum

protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Tarun Sharma **Consultant Pathologist**



Dr. Itisha Dhiman Pathologist





View Report

Page 11 Of 17

View Details





PATIENT NAME : KA	VIA SANTOSH	REF. DOCTOR : DR. BOB				
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156		ACCESSION NO : 0061XC002081 PATIENT ID : KAVIF23037661 CLIENT PATIENT ID: ABHA NO :		AGE/SEX :48 Years Female DRAWN : RECEIVED :24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16		
Test Report Status	<u>Final</u>	Results	Biologica	l Reference	e Interval	Units
	CLIN	ICAL PATH - URINALYSI	S			
MEDI WHEEL FULL B	ODY HEALTH CHECKUP B	ELOW 40FEMALE				
PHYSICAL EXAMINA	TION, URINE					
COLOR		PALE YELLOW				
APPEARANCE		CLEAR				
CHEMICAL EXAMINA	TION, URINE					
PH		6.0	4.7 - 7.5			
SPECIFIC GRAVITY		1.025	1.003 - 1	035		
PROTEIN		NOT DETECTED	NOT DET	ECTED		
GLUCOSE		NOT DETECTED	NOT DET	ECTED		

MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	3-5	0-5	/HPF
EPITHELIAL CELLS	5-7	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	DETECTED (+)	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NORMAL

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NORMAL

Interpretation(s)

KETONES

BILIRUBIN

UROBILINOGEN

LEUKOCYTE ESTERASE

BLOOD

NITRITE

Dr. Tarun Sharma Consultant Pathologist



Dr. Itisha Dhiman Pathologist







View Report

View Details





PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR :	DR. BOB
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0061XC002081 PATIENT ID : KAVIF23037661 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :48 Years Female DRAWN : RECEIVED :24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16
Test Report Status Final	Results Biological	Reference Interval Units

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

1

Dr. Tarun Sharma **Consultant Pathologist**



Dr. Itisha Dhiman Pathologist



Page 13 Of 17

Τ.

View Details





PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : D	DR. BOB
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0061XC002081	AGE/SEX :48 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KAVIF23037661 CLIENT PATIENT ID:	DRAWN : RECEIVED : 24/03/2024 11:19:09
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :28/03/2024 15:15:16
	1	1

Test Report Status <u>Final</u>

Results

Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD

SAMPLE NOT RECEIVED

Dr. Tarun Sharma Consultant Pathologist



Dr. Itisha Dhiman Pathologist





View Report

Page 14 Of 17

View Details





Biological Reference Interval Units

PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : D	R. BOB
	ACCESSION NO : 0061XC002081	AGE/SEX :48 Years Female
	PATIENT ID : KAVIF23037661	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 24/03/2024 11:19:09
NEW DELHI 110030	ABHA NO :	REPORTED :28/03/2024 15:15:16
8800465156		

Test	Report	Status	<u>Final</u>

SPECIALISED CHEMISTRY - HORMONE

Results

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE				
THYROID PANEL, SERUM				
T3	131.80	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	ng/dL	
Τ4	7.18	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL	
TSH (ULTRASENSITIVE)	3.470	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Association 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000		

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist**





Page 15 Of 17



PATIENT NAME: KAVIA SANTOSH REF. DOCTOR : DR. BOB CODE/NAME & ADDRESS : C000138375 ACCESSION NO : 0061XC002081 AGE/SEX :48 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : KAVIF23037661 : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 24/03/2024 11:19:09 DELHI ABHA NO REPORTED :28/03/2024 15:15:16 : NEW DELHI 110030 8800465156

Test Report Status <u>Final</u>

Results

Biological Reference Interval Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist





Page 16 Of 17

View Details





PATIENT NAME : KAVIA SANTOSH	REF. DOCTOR : DR. BOB			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0061XC002081 PATIENT ID : KAVIF23037661 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :48 Years Female DRAWN : RECEIVED :24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

CONDITIONS OF LABORATORY TESTING & REPORTING

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
 Result delays could occur due to unforeseen

circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

Test results cannot be used for Medico legal purposes.
 In case of queries please call customer care

(91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist





View Report

Page 17 Of 17

View Details

